Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1	137. (Canceled).
1	38. (Currently Amended) A method as in claim 54, wherein for inhibiting
2	restenosis in a blood vessel following recanalization of the blood vessel, said method
3	comprising:
4	implanting a vascular prosthesis in the blood vessel; and
5	releasing methylprednisolone is released from the prosthesis at a rate between 5
6	μ g/day to 200 μ g/day.
1	39. (Previously Presented) A method as in claim 38, wherein
2	methylprednisolone is released at a rate between 10 μ g/day to 60 μ g/day.
1	40. (Currently Amended) A method as in claim <u>54</u> 38 , wherein
2	methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a
3	vascular environment.
1	41. (Previously presented) A method as in claim 40, wherein
2	methylprednisolone is released within a time period of 7 days to 21 days in a vascular
3	environment.
1	42. (Currently Amended) A method as in claim <u>55</u> 38, further comprising
2	releasing the at least one other substance simultaneously with methylprednisolone from the
3	prosthesis.

1

2	releasing the at least one other substance sequentially with methylprednisolone from the
3	prosthesis.
1	44. (Canceled).
1	45. (Currently Amended) A method as in claim <u>54</u> 38 , wherein the releasing
2	comprises delaying substantial release of methylprednisolone for at least one hour following
3	implantation of the prosthesis.
1	46. (Previously Presented) A method as in claim 45, wherein delaying
2	release comprises slowing releasing methylprednisolone from a reservoir with a material that at
3	least partially degrades in a vascular environment over said one hour.
1	47. (Previously Presented) A method as in claim 45, wherein delaying
2	release comprises slowing releasing methylprednisolone with a matrix that at least partially
3	degrades in a vascular environment over said one hour.
1	48. (Previously Presented) A method as in claim 45, wherein delaying
2	release comprises slowing releasing methylprednisolone with a nondegradable matrix that
3	allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.
1	49. (Previously Presented) A method as in claim 45, wherein delaying
2	release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows
3	diffusion of methylprednisolone through the barrier after said one hour.
1	50. (Original) A method as in any one of claims 47-49, wherein the
2	prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.
1	5153. (Canceled).

43. (Currently Amended) A method as in claim 55 38, further comprising

l	54. (Previously Presented) A method for inhibiting restenosis in a blood
2	vessel following recanalization of the blood vessel, said method comprising:
3	implanting a vascular prosthesis in the blood vessel; and
1	releasing methylprednisolone and mycophenolic acid from the prosthesis when
5	implanted in the blood vessel.
ı	55. (Previously Presented) A method for inhibiting restenosis in a blood
)	vessel following recanalization of the blood vessel, said method comprising:
- }	implanting a vascular prosthesis in the blood vessel; and
, 1	releasing methylprednisolone and at least one other substance in addition to
+	
5	methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the at least
5	one other substance comprises mizoribine.
	56. (Currently Amended) A method as in claim <u>54</u> 38, further comprising
2	releasing at least one other substance in addition to methylprednisolone from the prosthesis
3	when implanted in the blood vessel, wherein methylprednisolone is substantially released
ļ	within a time period of 2 days to 3 months.
	57. (Canceled).
l	58. (Currently Amended) A method as in claim <u>54</u> 56 , wherein
2	methylprednisolone and mycophenolic acid the at least one additional substance are released
·	simultaneously.
,	Simultaneously.
	59. (Currently Amended) A method as in claim <u>54</u> 56 , wherein
2	methylprednisolone and mycophenolic acid the at least one additional substance are released
3	sequentially.
	6061. (Canceled)

(New) A method as in claim 55, wherein methylprednisolone is released 1 62. from the prosthesis at a rate between 5 μ g/day to 200 μ g/day. 2 63. (New) A method as in claim 62, wherein methylprednisolone is released 1. at a rate between 10 μ g/day to 60 μ g/day. 2 (New) A method as in claim 55, wherein methylprednisolone is released 1 64. 2 from the prosthesis within a time period of 1 day to 45 days in a vascular environment. 65. (New) A method as in claim 64, wherein methylprednisolone is released 1 within a time period of 7 days to 21 days in a vascular environment. 2 1 66. (New) A method as in claim 55, wherein the releasing comprises delaying substantial release of methylprednisolone for at least one hour following implantation 2 of the prosthesis. 3 67. (New) A method as in claim 66, wherein delaying release comprises 1 slowing releasing methylprednisolone from a reservoir with a material that at least partially 2 3 degrades in a vascular environment over said one hour. (New) A method as in claim 66, wherein delaying release comprises 1 68. slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular 2 3 environment over said one hour. 1 69. (New) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of 2 3 methylprednisolone through the nondegradable matrix after said one hour. 70. (New) A method as in claim 66, wherein delaying release comprises 1 slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of 2

methylprednisolone through the barrier after said one hour.

3

PATENT

Appl. No. 09/782,804 Amdt. dated February 15, 2005 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

- 1 71. (New) A method as in any one of claims 68-70, wherein the prosthesis is
- 2 coated with the matrix or barrier by spraying, dipping, deposition, or painting.
- 1 72. (New) A method as in claim 55, wherein methylprednisolone is
- 2 substantially released within a time period of 2 days to 3 months.